More from Renaissance Capital

Biotech Stemline Therapeutics files for $50 million US IPO

By Renaissance Capital,  April 02, 2012, 07:53:24 PM EDT

Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, filed on Monday with the SEC to raise up to $50 million in an initial public offering. The New York, NY-based company has two lead candidates, both in Phase 2 clinical trials, for the treatment of leukemia and brain cancer.

Stemline, which was founded in 2003, plans to list on the NASDAQ under the symbol STML. Oppenheimer & Co. and JMP Securities are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: Investing, IPOs

Referenced Stocks:



Latest News Video

Sprint Boosts Bid For Clearwire, and More
Sprint Boosts Bid For Clearwire, an...
Lifeguard Describes Dragging Shark Into Deeper Water
Lifeguard Describes Dragging Shark ...
Focus on Looking For Tornado Survivors, and More
Focus on Looking For Tornado Surviv...
Obama Pledges Support For Tornado Victims
Obama Pledges Support For Tornado V...


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.43 0.08  0.59%
YGE $ 3.93 0.83  26.77%
CLWR $ 3.43 0.17  5.21%
F $ 14.872 0.18  1.18%
MSFT $ 34.88 0.20  0.57%
S $ 7.375 0.09  1.17%
CSCO $ 23.74 0.21  0.86%
INTC $ 24.195 0.12  0.48%